Background
==========

Family Flaviviridae comprises small enveloped pathogens classified in three genera: *Flavivirus*, *Pestivirus*, and *Hepacivirus*. Members of these genera cause various diseases in humans and other animals such as birds, horses and pigs. The only genera *Flavivirus*contain more than 70 members including Hepatitis C Virus (HCV), Dengue virus, West Nile virus and tick-borne encephalitis virus \[[@B1]-[@B3]\].

HCV is a positive sense RNA virus affecting approximately 180 million people world wide and rate of infection in Pakistani population is about 10 million \[[@B4],[@B5]\]. HCV genome contributes about 9400 nucleotides that encode single polyprotein of approximately 3010 to 3033 amino acids in length \[[@B6]\]. This single polyprotein is processed by viral as well as host proteases into three structural proteins (i.e. core, E1 and E2) and four non-structural proteins (i.e. NS2, NS3, NS4, and NS5A) \[[@B7]\].

HCV mainly spreads via blood supply, reuse of glass syringes and needles, unsterilized medical equipment, use of tooth brushes of HCV patients, etc \[[@B7]\] and causes of acute and chronic infections \[[@B8]\]. Clinical demonstrations of acute Hepatitus C Viral infection include Jaundice, Fever, Myalgia, Fatigue, Lethargy, Increased ALT, Anorexia and Fulminant hepatic failure \[[@B7]\]. About 80% of HCV infected individuals develop chronic infections \[[@B9]\]. Chronic liver infections develop chronic hepatitis, cirrhosis and hepatocellular carcinoma within a period of 10, 20 and 30 years respectively followed by viral infection \[[@B10],[@B11]\]. Out of 70-80% chronically infected individuals, 20% develop cirrhosis and 1-5% individuals suffer from final stage of liver diseases \[[@B12]\]. Hepatic steatosis is the accumulation of lipids in hepatocytes and is reported for the cause of cirrhosis \[[@B13]\] with the more severe cases being reported in patients infected with HCV genotype 3a \[[@B14]\]. The prevelance of steatosis in Pakistani population is about 61.5-65.5% compared with 32.8-81.2% in western countries \[[@B15]\]. The percentage of males infected with HCV chronic liver stage is higher then females with the age of patients between 40-50 years \[[@B5]\].

HCV is classified into six genotypes each heaving various subtypes \[[@B16]-[@B18]\]. These genotypes are distributed differently in various parts of the world with the genetic variance between them is about one third. The genotypes 1, 2 and 3 have world wide distribution. But the significant differences are observed in subtype distribution. Subtype 1a is mostly found in North America and Europe followed by 2b and 3a. Subtype 1b is frequently found in South East Europe and Tunisia and 2c in North Italy. Genotype 4 is mainly restricted to Middle East and Central Africa and genotype 5 in South Africa. Genotype 6 is distributed throughout South East Asia and also being isolated from Hong Kong and Vietnam \[[@B17]\]. The most frequent HCV genotypic distribution in Pakistan is 3a \[49.05%\] followed by 3b \[17.66%\] \[[@B19]\]. The knowledge of HCV distribution is crucial for treatment therapy and vaccination because of its predictive value in terms of response to antiviral therapy and vaccination. Effective responses to antiviral therapy are normally associated with genotype 2 and 3 in comparison to any other genotype \[[@B20]\].

HCV replicates at about 10^12^new HCV viruses/day. Replication is carried out by RNA dependent RNA polymerase. RNA polymerase lacks the \"proofreading\" ability that ensures the high mutation rate of about 8-18 mutations in genomic RNA/year \[[@B21],[@B20]\]. Such a high mutation rate limits the treatment therapy and vaccination. The current treatment therapy for HCV is INF alpha along with ribavirin limited to about 50% population \[[@B22]\]. Although the response rate is not much deterring, but high dosage, long-term treatment and side effects limits the usage \[[@B23],[@B21]\]. There is the possibility that after next few years, new antiviral agents such as inhibitors of the viral protease, helices or polymerase will further improve the response rate of the current therapeutic agents. However, antiviral therapy is not affordable in most developing countries, where the prevalence of HCV is generally the highest. Thus, given the huge reservoir of HCV worldwide, the development of an effective vaccine may be the cheapest way to control disease associated with HCV infection.

Development of an effective HCV vaccine requires understanding of immune response. Viral immune response is associated with Major Histocompatabiliy complex protein (MHC) and T lymphocytes/T cell. MHC are classified into 2 broad categories, MHC I and MHC II \[[@B24]\]. MHC initially recognizes the viral antigenic epitopes and presents to T lymphocytes for degradation. MHC I presents the antigenic epitopes to CD8+ T cells and MHC II presents to CD4+ T cells for viral degradation \[[@B25],[@B26]\]. CD8 T cells also referred to as cytotoxic T cells (CTL or Tc), limit viral infections by initial recognizing and their subsequent killing infected cells and secreting cytokines. CD4 T referred to as helper cells or Th cells and provides growth factors and signals for generation and maintenance of CD8 T cells \[[@B27]\]. T cells recognize the antigens only when they are associated with MHC, surface glycoprotein exposed on surface of all vertebrate cells. The selection of T cell epitopes is also important because these are linear and hence easy to synthesize.

A particular vaccine developed against HCV can\'t be effective for Pakistani population because of variations in HCV genomic sequences and distribution with regard to geographical area. Since a large number of Pakistani population is infected by HCV3a and number of patients enrolled in public and hospitals is increasing day by day. So there is a current need to develop a vaccine against HCV in particular to HCV3a that will cover approximately maximum Pakistani population. The current vaccines are DNA vaccine, Peptide vaccine and epitopic vaccines. Epitopes are the small antigenic segments of viral proteins and causes infections in the host. Epitopic vaccines provide more potent and controlled immune response and eliminates the potential lethal effects of the use of whole viral proteins \[[@B28]\]. Promiscuous epitopes (epitopes capable of binding maximum number of HLA alleles) may overcome the population coverage. Secondly the conserved epitopes reduces antigen escape associated with the viral mutation \[[@B29]\]. So the present study was designed for the prediction of promiscuous epitopes and to analyze their conservancy in general population. Any mutation in the peptide/epitope will lower the conservancy, so it was hypothesized to analyze the pI value of the mutated amino acid residue, that if remain in the range as was in original epitope provides the likeliness of that particular epitope to be used for epitopic vaccine design having an effective control over viral mutation, immune response with minimum side effects.

Methods
=======

Sequence Retrieval and Analysis
-------------------------------

The sequence of fully sequenced HCV 3a genome and protein of Pakistani origin was retrieved from NCBI \[GU294484\]. The number of individual bases in the genome i.e. the number of adenine; cytosine, guanine and thymine were calculated from DDBJ database. The molecular weight of proteins, percentage of highly repeated amino acid and the least repeated amino acid in the viral protein was calculated by using sequence and search analysis tool at PIR database (<http://pir.georgetown.edu/>).

Epitope Prediction
------------------

Promiscuous epitopes of HCV 3a viral proteins were predicted for HLA I and HLA II binding alleles using freely available immunoinformatics tools such as ProPred I, and ProPred respectively. In comparison to other epitope prediction tools, Propred 1 and Propred cover maximum number of Human Leukocyte antigens i.e. HLA and being used for epitopic prediction for HBV and tuberculosis. ProPred1 allows the user to predict antigenic apitopes for 47 MHC I alleles and ProPred allows epitopes prediction for 51 MHC II alleles. Predictions through these tools can be carried out at various thresholds from 1 to 10%. The algorithms designed for the working of these tools are based on linear coefficients of matrices. Maximum of the matrics were retrieved from BIMASS where the score of each peptide is calculated in multiplication and/or sum up manner. For example the score of following peptide \"PACDPGRAA\" can be calculated by using following equation:

Score = P(1) × A(2) × C(3) × D(4) × P(5) × G(6) × R(7) × A(8) × A(9)

Score = P(1) + A(2) + C(3) + D(4) + P(5) + G(6) + R(7) + A(8) + A(9)

Where P (1) is score of P at position 1.

Only the promiscuous epitopes with score higher than the chosen threshold score were assigned as predicted epitopes for the selected HLA alleles \[[@B30]\]. For the following study the default threshold i.e. 4% was used where the sensitivity and specificity are nearly the same for most of the HLA alleles available in ProPred1 and ProPred server. Moreover, MHC I alleles were predicted by keeping the proteosome and immunoproteosome filters on at 5% threshold because most of the MHC binders having a proteosomal cleavage site at C-terminal have higher likelihood to be T-cell epitopes \[[@B31]\]. The predicted promiscuous epitopes were positioned in the table in a decreasing order of their score.

Epitope Conservancy Analysis
----------------------------

All the predicted epitopes of HCV 3a proteins of Pakistani origin were subjected for worldwide conservancy analysis among HCV genotype 1, 2 and 3. 5 sequences against each HCV protein (used for epitope prediction) were retrieved from NCBI randomly. The predicted epitopes of HCV 3a (Pakistani origin) along with 5 selected sequences of individual genotypes (genotype 1, 2 and 3; one at a time) were submitted to epitope conservancy analysis tool available at IEDB database (<http://tools.immuneepitope.org/tools/conservancy/iedb_input>). All the epitopes having 77-100% conservancy were selected while rejecting the epitopes having variation at the anchor residues. The anchor residues in the predicted epitopes were highlighted by making it bold. The epitopes that were 100% conserved in the selected proteins of the 3 viral genotypes 1, 2 and 3 were also fully bold. Epitopes with 88/77% conservancy were with single or double amino acid variation respectively and to highlight them bold format was used in the conservancy column against each genotype.

Asteric sign (\*) indicates that one out of five selected sequences either does not respond to epitope conservancy or have conservancy lower then 77%. Double asteric sign (\*\*) indicates that only one sequence responds for 77-100% conservancy to the selected epitope.

Validation of varied amino acids using pI value
-----------------------------------------------

The Peptides with single or double amino acid variation were analyzed for their hydropathic characteristics or pI value \[[@B32]\]. The pI gives the information that the varied residue retained the amino acid group or diverted from its normal group in a particular peptide under consideration and thus provides information to be used or their rejection. All the varied amino acid residue with diverted group (with considerable change of pI value) were separated from other using superscript \"D\" for single variation and \"DD\" for diverted group for doubly varied residues. The superscript \"D\" in doubly varied residues of particular peptides represents the partial variation i.e. one of the varied residue retained the amino acid group while other residue shifted the amino acid group by a considerable change of pI value.

Results
=======

HCV 3a genome of Pakistani origin comprises 9474 bp with GC content 2622 and 2700 respectively. The GC contents are 12.35% higher then AT contents. The genome encodes a polyprotein that subsequently get fragmented into structural and non structural protein of obvious molecular weight. The envelope protein E2 comprises highest moleculat weight 38755.3 KDa (Table [1](#T1){ref-type="table"}). Leucine (L) a neutral nonpolar amino acid residue has the highest percent of repetition (13.1%) in E2 protein. The least repeated residue of E2 is a basic polar Lysine (K) (1.4%). The shortest segment viral protein is NS4a (5751.69 KDa molecular weight) comprising 54 amino acid residues. Leucine (L) and Valine (V) have highest percentage of repetition (14.8) and Histidine (H), Methionine (M), Threonine (T) and Tryptophan (W) are the least repeated amino acid residues (1.9%). The molecular weight of other viral proteins and percent repetition of their amino acid residue for were listed in Table [1](#T1){ref-type="table"}. The percentage of amino acid residues gives an out look for their pI value and their probability of incidence in the antigenic epitopes.

###### 

It comprises the data of HCV genome size, Proteins, Molecular weight and %age of highly repeated and least repeated amino acid residues in individual bases

  Bases      **No**.   Proteins   aa Number   **Mol. Wt**.   Highly repeated aa   \% of repetition   Least repeated aa   \% of repetition
  ---------- --------- ---------- ----------- -------------- -------------------- ------------------ ------------------- ------------------
  Total bp   9474      Capsid     114         12985.8        R                    18.4               C/F                 0.9
                                                                                                                         
  A          1974      Core       75          7638.88        L                    16                 E/K/M/Y             1.3
                                                                                                                         
  C          2700      E1         190         20643.9        V                    11.1               E                   1.1
                                                                                                                         
  G          2622      E2         350         38755.3        L                    13.1               K                   1.4
                                                                                                                         
  T          2178      NS3        149         15423.6        A/G                  11.4               N                   0.7
                                                                                                                         
                       NS4a       54          5751.69        L/V                  14.8               H/M/T/W             1.9
                                                                                                                         
                       NS4b       194         20167.5        A                    13.4               C                   0.4
                                                                                                                         
                       NS5a-1a    62          6700.72        G                    14.5               E/D                 1.6
                                                                                                                         
                       NS5a-1b    101         11224.6        P                    11.9               K/W                 1

F (Phenylalanine), I (Isoleucine), L (Leucine), M (Methionine), V (Valine), W (Tryptophan) and Y (Tyrosine) were mainly the anchor residues for MHC II predicted epitopes and are nonpolar in nature. Total 150 epitopes were predicted against 51 alleles of MHC II (Table [2](#T2){ref-type="table"}). The highest number of epitopes was represented by E2 protein comprising 20% of all MHC II predicted epitopes. VFLLNPCGL, FVILVFLLL, WHINSTVLH, FNLLDVPKA, LELINTHGS, VQYLYGVGS are the promiscuous binders of 45-50 MHC II alleles. E2 is followed by NS2 and NS4B proteins representing 14.66% of the predicted MHC II epitopes. In case of NS2 VRAHVLVRL, VILLTSLLY and VRLCMFVRS are the best binders both in term of score and the HLA allele coverage (50-51 MHC II alleles). FFNILGGWV, VNLLPAILS and VVNLLPAIL are the best binders of NS4b protein both in terms of HLA coverage (41 HLA coverage for the first epitope and 51 for the next 2 epitopes) and binding efficiency. LVVGVICAA, FNILGGWVA, WQKLEAFWH, IQYLAGLST and VVGVICAAL are also the epitopes of good quality covering 31 to 35 HLA alleles available in ProPred. For the NS5a_1a only three epitopes (MRLAGPRTC, FISCQKGYK and VVSTRCPCG) were predicted as promiscuous binders with the binding score higher then the selected threshold. Out of these three epitopes MRLAGPRTC is capable of binding all the HLA alleles available in ProPred server while FISCQKGYK and VVSTRCPCG bind 22 and 25 HLA alleles respectively. The predicted promiscuous binders against other proteins were also summarized in table [2](#T2){ref-type="table"}.

###### 

Predicted HLA II epitopes HCV Proteins of Pakistani origin and their conservancy in Genotype 1, 2 and 3 worldwide

  Epitope start Position   Predicted T-cell epitopes   HLA alleles   HCV genotype 1             HCV Genotype 2             HCV Genotype 3
  ------------------------ --------------------------- ------------- -------------------------- -------------------------- ----------------------
  **Capsid**                                                                                                               
                                                                                                                           
  43                       **L**GVRATRKA               23            LGVRATRK**T**^D^           LGVRATRK**T**              LGVRATRK**T**^D^
                                                                                                                           
  36                       **L**PRRGPR**L**G           15            **LPRRGPRLG**              **LPRRGPRLG**              **LPRRGPRLG**
                                                                                                                           
  106                      **W**GPNDPRRR               16            WGP**T**DPRRR              WGP**T**DPR**H**R^D^       WGPNDPRRR
                                                                                                                           
  34                       **Y**VLPRRGPR               24            Y**L**LPRRGPR              Y**L**LPRRGPR              YVLPRRGPR
                                                                                                                           
  21                       **V**KFPGGGQI               8             **VKFPGGGQI \***           **VKFPGGGQI**              **VKFPGGGQI**
                                                                                                                           
  35                       **V**LPRRGPRL               9                                                                   VLPRRGPRL
                                                                                                                           
  45                       **V**RATRKASE               25            VRATRK**T**SE^D^           VRATRK**T**SE^D^           VRATRK**T**SE^D^
                                                                                                                           
  30                       **V**GGV**Y**VLPR           39            VGGVY**L**LPR \*           VGGVY**L**LPR              VGGVYVLPR
                                                                                                                           
  15                       **I**RRPQDVKF               6                                                                   IRRPQDVKF
                                                                                                                           
  95                       **W**LLSPRGSR               28            **WLLSPRGSR**              **WLLSPRGSR**              **WLLSPRGSR**
                                                                                                                           
  29                       **I**VGGVYVLP               3             IVGGVY**L**LP \*           IVGGVY**L**LP              IVGGVYVLP
                                                                                                                           
  82                       **W**PLYGNEGC               10            **WPLYGNEGC**              **WPLYGNEGC**              **WPLYGNEGC**
                                                                                                                           
  85                       **Y**GNEGCGWA               11            **YGNEGCGWA**              **YGNEGCGWA \***           **YGNEGCGWA**
                                                                                                                           
  33                       **V**YV**L**PRRGP           1             VY**L**LPRRGP              VY**L**LPRRGP              VYVLPRRGP
                                                                                                                           
  **Core**                                                                                                                 
                                                                                                                           
  61                       **F**L**L**ALLSCL           50            FLLALLSCL                  FLLALLSC**I**              FLLALLSCL
                                                                                                                           
  64                       **L**ALLSCLIH               45            LALLSCL**TV**^DD^                                     LALLSCLIH \*
                                                                                                                           
  15                       **F**ADLMGYIP               41            **FADLMGYIP**              **FADLMGYIP**              **FADLMGYIP**
                                                                                                                           
  24                       **L**VGAPVGGV               44            LVGAP**L**GG**A**                                     LVGAPVGGV \*
                                                                                                                           
  63                       **LL**ALLSCLI               36            LLALLSCL**T**^D^           LLALLSC**IT**^D^           LLALLSCLI \*
                                                                                                                           
  62                       **FLL**ALLSCL               24            FLLALLSCL                  FLLALLSC**I**              FLLALLSCL \*
                                                                                                                           
  32                       **V**ARALAHGV               10                                       VARALAHGV                  VARALAHGV
                                                                                                                           
  21                       **Y**IPLVGAPV               28            YIPLVGAP**L**              YIP**V**VGAP**L**          YIPLVGAPV
                                                                                                                           
  19                       **M**GYIPLVGA               26            MGYIPLVGA                  MGYIP**V**VGA              MGYIPLVGA
                                                                                                                           
  **E1**                                                                                                                   
                                                                                                                           
  58                       **Y**VGATTASI               41                                                                  YVGATTASI \*
                                                                                                                           
  140                      **M**VVAHILRL               39                                                                  MVVAHILRL\*
                                                                                                                           
  2                        **W**RNTSG**LY**V           27                                                                  WRNTSGLYV
                                                                                                                           
  138                      **V**G**M**VVAHIL           28                                                                  
                                                                                                                           
  56                       **V**K**Y**VGATTA           21                                                                  V**R**YVGATTA^D^\*
                                                                                                                           
  9                        **Y**VLTNARSN               31                                                                  YVLTN**DC**SN^DD^
                                                                                                                           
  161                      **W**GVLAGLA**Y**           15            WGVLAG**M**AY              WGV**VF**GLAY              WG**I**LAGLAY
                                                                                                                           
  93                       **F**LVGQAFTF               11            FLVGQ**L**FTF                                         FLVGQAFTF
                                                                                                                           
  181                      **I**IMVMFSGV               91                                                                  IIMVMFSGV
                                                                                                                           
  130                      **M**MMNWSPAV               35            MMMNWSP**TA**^D^                                      MMMNWSPA**M**
                                                                                                                           
  134                      **W**SPA**V**G**M**VV       6                                                                   WSPA**M**GMVV \*
                                                                                                                           
  132                      **M**N**W**SPA**V**G**M**   14                                                                  MNWSPA**M**GM \*
                                                                                                                           
  169                      **Y**YT**M**QGNWA           18                                                                  YY**S**MQGNWA
                                                                                                                           
  47                       **W**TPMTPTVA               21                                                                  WTP**V**TPTVA \*
                                                                                                                           
  172                      **M**QGNWAKVA               25            M**V**GNWAKV**L**^D^       MQG**A**WAKV**I**^D^       WTP**V**TPTVA^D^\*
                                                                                                                           
  145                      **I**LRLPQTLF               19                                                                  ILRLPQTLF
                                                                                                                           
  **E2**                                                                                                                   
                                                                                                                           
  122                      **M**LPHHRPVV               3                                                                   
                                                                                                                           
  151                      **V**FLLNPCGL               48                                                                  
                                                                                                                           
  337                      **W**E**F**VILVFL           4                                                                   WEF**IV**LVFL
                                                                                                                           
  339                      **F**VI**L**VFLLL           46                                                                  F**IV**LVFLLL
                                                                                                                           
  35                       **W**HINSTVLH               41                                                                  
                                                                                                                           
  342                      **L**VFLLLADA                             L**L**FLLLADA              L**L**FLLLADA              LVFLLLADA
                                                                                                                           
  100                      **V**LLAYAPRP               50                                                                  
                                                                                                                           
  198                      **F**RPLLPHRL               47                                                                  
                                                                                                                           
  218                      **V**RLGALVDT               12                                                                  
                                                                                                                           
  62                       **F**NLLDVPKA               45                                                                  
                                                                                                                           
  26                       **L**ELINTHGS               46                                                                  
                                                                                                                           
  57                       **F**YYHK**F**NLL           12            FYYHKFN**SS**^D^                                      FYYHKFN**ST**^DD^
                                                                                                                           
  83                       **V**GPLDRCQH               26                                                                  
                                                                                                                           
  58                       **Y**YHK**F**NLLD           24                                                                  
                                                                                                                           
  286                      **L**LHSTTELA               17            LLHSTTE**W**A                                         LLHSTTELA
                                                                                                                           
  129                      **V**VVGTTDPK               14            VVVGTTD**KL**^DD^          VVVGTTDRL^DD^\*            VVVGTTD**A**K
                                                                                                                           
  320                      **V**QYLYGVGS               46            VQYLYGVGS                                             VQYLYGVGS
                                                                                                                           
  159                      **L**LVVGGLGG               14                                                                  
                                                                                                                           
  293                      **L**AILPCSFT               7                                                                   LAILPCSFT
                                                                                                                           
  335                      **L**KWE**F**VI**L**V       4                                                                   LKWEF**IV**LV
                                                                                                                           
  322                      **Y**LYGVGSGM               5             YLYGVGS**SI**^D^                                      YLYGVGSGM
                                                                                                                           
  300                      **F**TPMPALST               17                                                                  FTPMPALST
                                                                                                                           
  245                      **F**YTVQGEDV               4                                                                   
                                                                                                                           
  18                       **I**VRGPEQRL               26                                                                  
                                                                                                                           
  100                      **V**LLAYAPRP               4                                                                   
                                                                                                                           
  257                      **V**WHRFTAAC               19            V**E**HR**L**TAAC^D^\*                                
                                                                                                                           
  206                      **L**LQETSRGH               8                                                                   
                                                                                                                           
  1                        **Y**ITGGTAAR               8                                                                   
                                                                                                                           
  267                      **W**TRGERCDI               10                                                                  WTRGERC**E**I
                                                                                                                           
  310                      **I**HLHQNIVD               11            IHLHQNIVD \*                                          IHLHQNIVD
                                                                                                                           
  **NS2**                                                                                                                  
                                                                                                                           
  101                      **V**RAHVLVRL               51                                                                  VRAHVLVRL
                                                                                                                           
  62                       **V**ILLTSLLY               50                                                                  VILLTSLLY \*
                                                                                                                           
  73                       **L**VFDIAKLL               24            LVFDI**T**KLL^D^\*         LVFDI**T**KLL^D^\*         L**I**FDI**T**KLL^D^
                                                                                                                           
  153                      **L**KDLAVATE               7                                                                   LKDLAVATE \*
                                                                                                                           
  113                      **F**VRSVTGGK               37                                                                  
                                                                                                                           
  130                      **V**GRWFNTYL               11                                                                  VGRWFNTYL \*
                                                                                                                           
  123                      **F**QMAILSVG               31                                                                  FQM**I**IL**H**VG^D^
                                                                                                                           
  137                      **Y**LYDHLAPM               21                                                                  YLYDHLAPM
                                                                                                                           
  74                       **V**FDIAKLLIA              23            VFDI**T**KLL**L**A ^D^\*   VFDI**T**KLL**L**A^D^      
                                                                                                                           
  107                      **LV**RLCMFVR               36                                                                  LVRLCM**L**VR
                                                                                                                           
  108                      **V**RLCMFVRS               51                                                                  VRLCM**L**VRS \*
                                                                                                                           
  89                       **YF**VRAH**V**LV           33                                                                  YFVRAHVLV
                                                                                                                           
  11                       **IL**VLFGFFT               15                                                                  
                                                                                                                           
  37                       **Y**AICRCESA               18                                       I**IN**GLPVSA^D^           Y**T**ICRCESA^D^\*
                                                                                                                           
  33                       **W**WNQ**Y**AICR           8                                                                   WWNQY**T**ICR^D^
                                                                                                                           
  185                      **I**LCGLPVSA               10            I**IN**GLPVSA \*           I**IN**GLPVSA              ILCGLPVSA
                                                                                                                           
  145                      **M**QHWAAAGL               18                                                                  MQHWAAAGL
                                                                                                                           
  50                       **V**PPLLARGS               21                                                                  VP**S**LLARGS^D^\*
                                                                                                                           
  88                       **LY**LIQAAIT               35                                                                  LYLIQ**T**AIT^D^\*
                                                                                                                           
  158                      **V**ATEPVIFS               14            VA**V**EPV**V**FS^D^       VA**V**EPV**V**FS          VATEPVIFS
                                                                                                                           
  37                       **Y**AICRCESA               19                                                                  YTICRCESA^D^\*
                                                                                                                           
  175                      **W**GADTAACG               11            WGADTAACG \*               WGADTAACG \*               WGADTAACG
                                                                                                                           
  **NS3**                                                                                                                  
                                                                                                                           
  4                        **V**QVLSTATQ               46            VQ**IV**STATQ              VQVLS**SV**TQ^D^           
                                                                                                                           
  43                       **L**QMYTNVDQ               42                                                                  
                                                                                                                           
  129                      **V**CTRGVAKA               21            VCTRGVAKA                  VC**A**RGVAK**S**^DD^\*    
                                                                                                                           
  24                       **W**TVYHGAGS               13            WTVYHGAG**T**              WTVYHGAG**N**              
                                                                                                                           
  84                       **VI**PARRRGD               18            VIP**V**RRRGD \*                                      
                                                                                                                           
  138                      **L**Q**F**IPVETL           45                                                                  
                                                                                                                           
  140                      **F**IPVETLST               43            FIPVE**N**L**G**T^D^                                  
                                                                                                                           
  6                        **V**LSTATQTF               19            **IV**STATQTF                                         
                                                                                                                           
  53                       **L**VGWPAPPG               29            LVGWPAP**Q**G              LVGWP**S**PPG^D^           
                                                                                                                           
  27                       **Y**HGAGSRTL               22            YHGAG**T**RT**I**                                     
                                                                                                                           
  14                       **F**LGTTLGGV               10                                                                  
                                                                                                                           
  77                       **L**VTREADV**I**           25            LVTR**H**ADVI ^D^\*        LVTR**N**ADVI^D^\*         
                                                                                                                           
  98                       **L**SPRPLACL               12                                       LSPRPL**ST**L^D^           
                                                                                                                           
  124                      **IF**RAAVCTR               44                                                                  
                                                                                                                           
  **NS4a**                                                                                                                 
                                                                                                                           
  23                       **V**VIVGHIEL               43            VVIVG**R**I**I**L^DD^      VVIVG**R**I**V**L^DD^      VVIVGHIEL
                                                                                                                           
  3                        **W**VLLGG**VL**AA          43            WVL**V**GGVLAA             WVL**V**GGVLAA             WVLLGGVLAA
                                                                                                                           
  4                        **V**L**L**GG**VL**AAL      40            VL**V**GGVLAAL             VL**V**GGVLAAL             VLLGGVLAAL
                                                                                                                           
  38                       **V**PDKEVL**Y**Q           11                                                                  VPDKEVLYQ \*
                                                                                                                           
  24                       **V**IVGH**I**ELG           8                                                                   VIVGHIELG
                                                                                                                           
  10                       **L**AALAA**Y**CLS          8             LAALAAYCL**T**\*           LAALAAYCLS                 LAALAAYCLS
                                                                                                                           
  16                       **Y**CLSVGC**V**V           6                                        YCLS**T**GCVV^D^           YCLSVGCVV
                                                                                                                           
  26                       **V**GHIELGGK               9                                                                   VGHIELGGK
                                                                                                                           
  25                       **I**VGHIELGG               29                                                                  IVGHIELGG
                                                                                                                           
  20                       **V**GCVVIVGH               15                                                                  VGCVVIVGH
                                                                                                                           
  9                        **VL**AALAA**Y**C           9             **VLAALAAYC\***            **VLAALAAYC**              **VLAALAAYC**
                                                                                                                           
  29                       **I**ELGGKPA**L**           14                                                                  IELGGKPAL
                                                                                                                           
  **NS4b**                                                                                                                 
                                                                                                                           
  81                       **FF**NILGGWV               41                                                                  FFNILGGWV
                                                                                                                           
  153                      **V**NLLPAILS               51            **VNLLPAILS**              **VNLLPAILS**              **VNLLPAILS**
                                                                                                                           
  152                      **VV**NLLPAIL               51                                                                  
                                                                                                                           
  39                       **W**N**F**VSG**I**QY       16            WNF**I**SGIQY              WNF**I**SGIQY              WNFVSGIQY
                                                                                                                           
  165                      **L**VVGVICAA               35            LVVGV**V**CAA              LVVGV**V**CAA              LVVGVICAA
                                                                                                                           
  82                       **F**NILGGWVA               32            **FNILGGWVA**              **FNILGGWVA**              **FNILGGWVA**
                                                                                                                           
  81                       **FF**NILGGWV               5                                                                   FFNILGGWV
                                                                                                                           
  63                       **LM**AFAASVT               9             LMAF**T**AS**I**T^D^       LMAF**T**A**A**VT^DD^      LMAF**T**ASVT^D^
                                                                                                                           
  27                       **W**QKLEAFWH               35                                       WQKLE**V**FW**A**^D^       WQKLEAFWH \*
                                                                                                                           
  167                      **V**GVICAALL               11            VGV**V**CAA**I**L          VGV**V**CAA**I**L          VGVICAA**I**L
                                                                                                                           
  45                       **I**QYLAGLST               35            **IQYLAGLST**              **IQYLAGLST**              **IQYLAGLST**
                                                                                                                           
  64                       **M**AFAASVTS               23            MAF**T**AS**I**TS          MAF**T**A**A**VTS^DD^      MAF**T**ASVTS^D^
                                                                                                                           
  84                       **I**LGGWVATH               24            ILGGWVA**AQ**^DD^          ILGGWVA**AQ**^DD^          ILGGWVATH
                                                                                                                           
  103                      **VV**SGLAGAA               10                                       V**GA**GLAGAA^D^           VVSGLAGAA
                                                                                                                           
  166                      **VV**GVICAAL               31            VVGV**V**CAA**I**          VVGV**V**CAA**I**          VGVICAA**I**L
                                                                                                                           
  85                       **L**GGWVATHL               3             LGGWVA**AQ**L^DD^          LGGWVA**AQ**L^DD^          LGGWVATHL
                                                                                                                           
  60                       **V**ASLMAFAA               15                                                                  VASLMAF**T**A^D^
                                                                                                                           
  41                       **F**VSG**I**QYLA           8             F**I**SGIQYLA              F**I**SGIQYLA              FVSGIQYLA
                                                                                                                           
  139                      **F**KIMGGELP               21                                       FKIM**S**GE**V**P^D^       FKIMGGE**F**P \*
                                                                                                                           
  9                        **L**QRATQQQA               14                                                                  LQRATQQQA \*
                                                                                                                           
  122                      **L**DILAGYGA               6                                                                   LDILAGYGA \*
                                                                                                                           
  104                      **V**SGLAGAAI               3                                                                   VSGLAGAAI
                                                                                                                           
  **NS5a_1a**                                                                                                              
                                                                                                                           
  39                       **M**RLAGPRTC               51            MR**IV**GPRTC \*           FISCQKGY**R**^D^\*         MRLAGPRTC\*
                                                                                                                           
  3                        **F**ISCQKGYK               22            F**F**SCQ**R**GYK^DD^\*                               FISCQKGYK \*
                                                                                                                           
  19                       **V**VSTRCPCG               25                                                                  V**M**STRCPCG \*
                                                                                                                           
  **NS5a_1b**                                                                                                              
                                                                                                                           
  73                       **L**LRDEIT**F**V           20            LLRDE**V**TF**Q**^D^\*     LLRDE**V**TF**Q**^D^\*\*   LLRDEITFV \*
                                                                                                                           
  16                       **W**RVAANSYV               33            WRVAA**EE**YV^DD^\*        WRVAA**SE**YV^D^           WRVAANSYV
                                                                                                                           
  55                       **F**TEVDGVRL               4             FTE**L**DGVRL\*            FTEVDGVRL \*\*             FTEVDGVRL
                                                                                                                           
  80                       **FV**VGLNSYA               25                                                                  FVVGLNSYA \*
                                                                                                                           
  32                       **F**HYITGATE               16                                                                  FHYITGATE
                                                                                                                           
  61                       **V**RLHRYAPP               27            VRLHRYAP**A**\*                                       VRLHRYAPP \*
                                                                                                                           
  87                       **Y**AIGSQLPC               20            Y**VV**GSQLPC \*           VRLHRYAP**A**^D^\*\*       YAIGSQLPC \*
                                                                                                                           
  23                       **YV**EVRRVGD               14            YVEV**T**RVGD^D^\*         YVEV**T**RVGD^D^\*\*       YVEVRRVGD

**Bold**amino acid residues in T-cell Epitope column indicates the anchor residues

**Bold**individual amino acid residues in HCV Genotype 1, 2 and 3 columns indicated the variation in peptide in comparison to the predicted epitope

\*Indicates that one of the protein sequence selected for epitope conservancy either does not respond or have conservancy lower then 70%

\*\* Indicates that only one of the protein sequence from selected sequences respond to epitope conservancy

^D^Indicates that amino acid residue in case of single/double variation diverted their group compared to primary epitope using pI value

^DD^Indicates that both amino acid residues in case of double variation diverted their group compared to primary epitope using pI value

Total 69 epitopes were predicted as promiscuous epitopes for MHC I alleles. The anchor residues in case of MHCI are quite varying both in amino acid residues and also in their nature. Mostly represented anchor residues are neutral nonpolar and neutral polar. However, quite small percentage of anchor residues were also acidic polar and basic polar in nature. The highest number of MHC I binding epitopes were represented by NS4b protein comprising 26% of all MHC I predicted epitopes. NFVSGIQYL epitope of NS4b is the best promiscuous binder of highest binding score. NS4b is followed by NS2, E2 and NS3 proteins representing 20.28% (NS2 epitopes) and 11.59% (for E2 and NS3). In case of NS2, 14 promiscuous epitopes were predicted with varying binding efficiency. GSRDGVILL, DGVILLTSL, WAAAGLKDL and LQVWVPPLL are the good binders both in term of score and the HLA allele coverage (21, 28, 27 and 28 alleles respectively). E2 predicted epitopes covers 20 to 28 HLA alleles except the PLLHSTTEL epitope that covers only 11 HLA alleles but with highest binding efficiency. NS3 epitopes covers 8 to 25 HLA alleles and were also ranked on the basis of their binding efficiency predicted by the score. The least represented epitopes were by NS5a_1a. It comprises only one epitope (HVKNGSMRL) as predicted promiscuous binders for 16 MHC I binding alleles. The promiscuous binders of MHC I for other proteins were also predicted and summarized in table [3](#T3){ref-type="table"}.

###### 

Predicted HLA I epitopes HCV Proteins of Pakistani origin and their conservancy in Genotype 1, 2 and 3 worldwide

  Epitope start Position   Predicted T-cell epitopes   HLA alleles   HCV genotype 1             HCV Genotype 2              HCV Genotype 3
  ------------------------ --------------------------- ------------- -------------------------- --------------------------- ------------------------
  **Capsid**                                                                                                                
                                                                                                                            
  38                       **R**RGPRLGVR               9             **RRGPRLGVR**              **RRGPRLGVR**               **RRGPRLGVR**
                                                                                                                            
  35                       **V**LPRRGPRL               25                                                                   VLPRRGPRL
                                                                                                                            
  **Core**                                                                                                                  
                                                                                                                            
  55                       **P**GCSFSIFL               8             **PGCSFSIFL**              **PGCSFSIFL**               **PGCSFSIFL \***
                                                                                                                            
  41                       **R**ALEDGINF               20                                       R**V**LEDG**V**NF \*\*      RALEDGINF \*
                                                                                                                            
  7                        **V**IDTLTCGF               15            VIDTLTCGF                  VIDT**I**TCGF \*            VIDTLTCGF \*
                                                                                                                            
  35                       **A**LAHGVRAL               24            ALAHGVR**V**L              ALAHGVRVL                   ALAHGVRAL \*
                                                                                                                            
  24                       **L**VGAPVGGV               18            LVGAP**L**GG**A**\*                                    LVGAPVGGV \*
                                                                                                                            
  26                       **G**APVGGVAR               9             GAP**L**GG**A**AR \*       GAP**L**GGVAR               GAPVGGVAR \*
                                                                                                                            
  **E1**                                                                                                                    
                                                                                                                            
  135                      **S**PAVGMVVA               14                                                                   SPA**M**GMVVA \*
                                                                                                                            
  86                       **G**DVCGAVFL               19            GD**L**CG**S**VFL^D^       GDVCGAV**MI**               GD**M**CGAVFL \*
                                                                                                                            
  144                      **H**ILRLPQTL               22                                                                   HILRLPQTL \*
                                                                                                                            
  156                      **I**AGAHWGVL               27            IAGAHWGVL                                              IAGAHWG**I**L
                                                                                                                            
  64                       **A**SIRGHVDL               25                                                                   ASIR**S**HVDL^D^
                                                                                                                            
  **E2**                                                                                                                    
                                                                                                                            
  285                      **P**LLHSTTEL               11                                       PLLHSTTE**W**^D^            PLLHSTTEL
                                                                                                                            
  305                      **A**LSTGLIHL               25            AL**T**TGLIHL                                          ALSTGLIHL
                                                                                                                            
  227                      **C**SFTPMP**A**L           20            CSFT**TL**PAL^D^\*                                     CSFTPMPAL
                                                                                                                            
  71                       **Q**QLQAHHFL               27                                                                   
                                                                                                                            
  157                      **C**GLLVVGGL               28                                                                   
                                                                                                                            
  212                      **R**GHIQPVRL               24                                                                   
                                                                                                                            
  6                        **T**AARGGQGL               25                                                                   
                                                                                                                            
  157                      **C**GLLVVGGL               28                                                                   
                                                                                                                            
  **NS2**                                                                                                                   
                                                                                                                            
  172                      **V**ITWGADTA               6                                                                    VITWGADTA \*
                                                                                                                            
  75                       **F**DIAKLLIA               12            FDI**T**KLL**L**A^D^       FDI**T**KLL**L**A^D^\*      FDI**T**KLLIA^D^
                                                                                                                            
  70                       **Y**PS**L**VFDIA           15                                                                   YPSL**I**FDI**T**^DD^
                                                                                                                            
  57                       **G**SRDGVILL               21            G**G**RD**A**VILL^D^\*\*   G**G**RD**A**VILL^D^\*      GSRDGVILL
                                                                                                                            
  60                       **D**GVILLTSL               26                                                                   DGVILLTSL \*
                                                                                                                            
  148                      **W**AAAGLKDL               27                                       WAA**S**GL**R**DL^DD^\*\*   WAAAGLKDL \*
                                                                                                                            
  50                       **V**PPLLARGS               11                                                                   VPPLLARGS \*
                                                                                                                            
  46                       **L**QVWVPPLL               28            L**H**VWVPPL**N**^DD^      L**H**VWVPPL**N**^DD^\*     LQVWVPPLL \*
                                                                                                                            
  117                      **V**TGGKYFQM               16                                                                   V**V**GGKYFQM^D^\*
                                                                                                                            
  65                       **L**TSLLYPS**L**           23                                                                   LTSLLYPSL
                                                                                                                            
  6                        **T**LGAGILVL               48                                                                   TLGAG**V**LVL \*
                                                                                                                            
  73                       **L**VFDIAKLL               31            LVFDI**T**KLL^D^           LVFDI**T**KLL^D^\*          L**I**FDI**T**KLL^D^
                                                                                                                            
  145                      **M**QH**W**AAAGL           26                                                                   MQHWAAAGL
                                                                                                                            
  178                      **D**TAACGDIL               21            DTAACGDI**I**              DTAACGDI**I**^D^\*          DTAACGDIL
                                                                                                                            
  **NS3**                                                                                                                   
                                                                                                                            
  119                      **G**HVAGIFRA               8             GH**AV**GIFRA \*           GHV**V**G**L**FRA \*        
                                                                                                                            
  27                       **Y**HGAGSRTL               14            YHGAG**T**RT**I**          YHGAG**NK**TL^D^            
                                                                                                                            
  128                      **A**VCTRGVAK               8             AVCTRGVAK                  AVCTRGVAK \*                
                                                                                                                            
  57                       **P**APPGAKSL               11            PAP**Q**GA**R**SL^DD^\*    P**S**PPG**T**KSL^DD^       
                                                                                                                            
  98                       **L**SPRPLACL               25                                       LSPRPL**ST**L^D^            
                                                                                                                            
  95                       **A**SL**L**SPRPL           24                                                                   
                                                                                                                            
  130                      **C**TRGVAKAL               20            CTRGVAKA**V**                                          
                                                                                                                            
  7                        **L**STATQTFL               24                                                                   
                                                                                                                            
  **NS4a**                                                                                                                  
                                                                                                                            
  3                        **W**V**L**LGGVLA           11            WVL**V**GGVLA              WVL**V**GGVLA               WVLLGGVLA
                                                                                                                            
  23                       **V**VIVGHIEL               21            VVIVG**R**I**I**L^DD^      VVIVG**R**I**V**L^DD^       VVIVGHIEL
                                                                                                                            
  10                       **L**AALAAYCL               24            LAALAAYCL \*               LAALAAYCL                   LAALAAYCL
                                                                                                                            
  5                        **L**LGGV**L**AAL           27            L**V**GGVLAAL              L**V**GGVLAAL               LLGGVLAAL
                                                                                                                            
  **NS4b**                                                                                                                  
                                                                                                                            
  96                       **P**QSSSAFVV               6                                                                    PQSSSAFVV
                                                                                                                            
  40                       **N**FVSGI**Q**YL           30            NF**I**SGIQYL              NF**I**SGIQYL               NFVSGIQYL
                                                                                                                            
  81                       **F**FNI**L**GGWV           13                                                                   FFNILGGWV
                                                                                                                            
  46                       **Q**YLAGLSTL               17            **QYLAGLSTL**              **QYLAGLSTL**               **QYLAGLSTL**
                                                                                                                            
  102                      **FV**VSGLAGA               9                                        FV**GA**GLAGA^D^            FVVSGLAGA
                                                                                                                            
  54                       **L**P**G**NPAVAS           14            LPGNPA**I**AS              LPGNPA**I**AS               LPGNPAVAS
                                                                                                                            
  161                      **S**PGALVVGV               14            **SPGALVVGV**              **SPGALVVGV**               **SPGALVVGV**
                                                                                                                            
  141                      **I**MGGELPNA               7                                                                    IMGGE**F**P**T**A^D^\*
                                                                                                                            
  164                      **A**LVVGVICA               11            ALVVGV**V**CA              ALVVGV**V**CA               ALVVGVICA
                                                                                                                            
  117                      **L**GRVLLDIL               22            LG**K**VL**V**DIL^D^\*     LG**K**VL**V**DIL^D^        LG**K**VLLDIL^D^\*
                                                                                                                            
  59                       **A**VASLMAFA               9             A**I**ASLMAF**T**^D^       A**I**ASLMAF**T**^D^        AVASLMAF**T**^D^
                                                                                                                            
  152                      **V**VNLLPAIL               15                                                                   
                                                                                                                            
  113                      **G**IGLGRVLL               24                                                                   GIGLG**K**VLL^D^\*
                                                                                                                            
  56                       **G**NPAVASLM               12            GNPA**I**ASLM              GNPA**I**ASLM               GNPAVASLM
                                                                                                                            
  52                       **S**TLPGNPAV               21            STLPGNPA**I**              STLPGNPAV                   STLPGNPAV
                                                                                                                            
  85                       **L**GGWVATHL               26            LGGWVA**AQ**L^DD^          LGGWVA**AQ**L^DD^           LGGWVATHL
                                                                                                                            
  145                      **E**LPNAEDVV               11                                                                   
                                                                                                                            
  99                       **S**SAFVVSGL               22                                                                   SSAFVVSGL
                                                                                                                            
  **NS5a_1a**                                                                                                               
                                                                                                                            
  33                       **H**VKNGSMRL               16            HVKNGSMR**I**\*            HVKNGSMR**I**\*\*           HVKNGSMRL
                                                                                                                            
  **NS5a_1b**                                                                                                               
                                                                                                                            
  49                       **V**PAAEFFTE               6             VPA**P**EFFTE \*           VPA**P**EFFTE \*\*          VPAAEFFTE
                                                                                                                            
  79                       **T**FVVGLNSY               10            TF**Q**VGLN**Q**Y^D^\*     TF**T**VGLNS**F**^D^\*      TF**T**VGLNSY^D^\*
                                                                                                                            
  76                       **D**EITFVVGL               19            DE**V**TF**Q**VGL^D^\*     DE**V**TF**T**VGL^D^\*      DEITF**M**VGL \*

**Bold**amino acid residues in T-cell Epitope column indicates the anchor residues

**Bold**individual amino acid residues in HCV Genotype 1, 2 and 3 columns indicated the variation in peptide in comparison to the predicted epitope

\*Indicates that one of the protein sequence selected for epitope conservancy either does not respond or have conservancy lower then 70%

\*\* Indicates that only one of the protein sequence from selected sequences respond to epitope conservancy

^D^Indicates that amino acid residue in case of single/double variation diverted their group compared to primary epitope using pI value

^DD^Indicates that both amino acid residues in case of double variation diverted their group compared to primary epitope using pI value

Out of total 150 predicted MHC II epitopes, 75.33% were (77-100%) conserve in genotype 3 (Table [1](#T1){ref-type="table"}) against the randomly selected viral proteins. Out of 75.33% conserved peptides of genotype 3, 71.68% peptides were 100% conserve while 22.12% peptides were having single residue variation (88% epitope conservancy). Only the 40% peptides of singly varied residues diverted their amino acid group and the pI value while 60% singly varied residues retained the amino acid group as was in the predicted epitope of HCV 3a proteins. 6.19% peptides comprised the 77% epitope conservancy because of double residue variation in the peptides of general population in contrast to predicted epitopes of HCV 3a of Pakistani origin. Out of 6.19%, doubly varied amino acid residues 42.85% peptides retained their amino acid group and nearly same pI value as in case of predicted epitope while 28.57% peptides were having partial group divertion and 28.57% (of doubly varied amino acid residues) peptides diverted their amino acid group because of considerable variation in the pI value. Similar data was also obtained for the HCV genotype 1 and 2 consisting 47.33% and 40.66% conservancy respectively. However, in contrast to genotype 3, only 23.94% predicted epitopes were 100% conserve in randomly selected sequences of genotype 1 and 22.95% in genotype 2. Their rate of single/double residue variation was also predicted and expressed as figure [1](#F1){ref-type="fig"}.

![**A comparative analysis of HCV 3a Predictive epitopes against MHC II alleles and their conservancy analysis in Genotype 1, 2 and 3 worldwide**.](1743-422X-8-55-1){#F1}

Out of total 69 predicted MHC I epitopes, 78.26% were (77-100%) conserve in genotype 3 (Table [2](#T2){ref-type="table"}) against the randomly selected viral proteins. Out of 78.26% conserved peptides of genotype 3, 72.22% peptides were 100% conserve while 22.22% peptides were having single residue variation (88% epitope conservancy). 40.66% peptides of singly varied residues retained the amino acid group as was in the predicted epitope of HCV 3a proteins while 58.33% singly varied residues diverted their amino acid group and the pI value. 5.5% peptides comprised the 77% epitope conservancy because of double residue variation in the peptides of general population in contrast to predicted epitopes of HCV 3a of Pakistani origin. Out of 5.5%, doubly varied amino acid residues 66.66% peptides were having partial group divertion and 33.33% (of doubly varied amino acid residues) peptides diverted their amino acid group because of considerable variation in the pI value. Similar data was also obtained for the HCV genotype 1 and 2 consisting 55.07% conservancy. However, in contrast to genotype 3, only 21.05% predicted epitopes were 100% conserve in randomly selected sequences of genotype 1 and 2. Their rate of single/double residue variation was also predicted and expressed as figure [2](#F2){ref-type="fig"}.

![**A comparative analysis of HCV 3a Predictive epitopes predicted against MHC I and their conservancy analysis in Genotype 1, 2 and 3 worldwide**.](1743-422X-8-55-2){#F2}

Discussion
==========

The modern technique for control of HCV infection is a vaccine preparation that can specifically induce antibody-mediated immunity. The rapid advancements in the computational methodologies and immunoinformatics/immuno-bioinformatics provide new strategies for the synthesis of antigen specific epitopic vaccine against infectious agents such as viruses and pathogens. Epitopic vaccine against HIV, malaria and tuberculosis provided promising results and supported the defensive and therapeutic uses of these vaccines \[[@B33]\]. Thus in the present study, a new systematic immunoinformatics approach was applied for the predicted antigenic epitopes of HCV 3a proteins of Pakistani origin followed by diversity and conservancy in other genotypes (1,2 and 3) in randomly selected HCV sequences from NCBI and mainly belong to Thailand, Cuba, UK, USA, China, Japan, France, Italy and Germany. The immunogenic epitopes identified were nanomers and could be used diagnostically to detect HCV specific CTL responses in the patients and after vaccination. A CTL based HCV vaccine might not efficient enough to prevent from infection but it might protect the body from the disease. The analysis showed that the minimal number of epitopes required to represent the complete anigenicity of the whole proteins are significantly smaller then required to represent full length proteins. The majority of the epitopes reported here had intermediate to high HLA binding affinity.

By the use of an efficient CTL based epitope delivery technology; the predicted epitopes could eventually become vaccines in their own or fused as polytopes. The design of the HCV vaccine using conserved epitopes can avoid viral mutation and thus provides more efficient results. The study shows that the predicted epitopes were highly conserved in HCV genotype 3 and also but less conserved in genotype 1 and 2 both for MHC I and MHC II. Moreover, to ensure the viral detection at all stages of its intracellular evolution we have used all the viral proteins. Therefore, the total number of predicted epitopes were also maximized in correspond to the number of covered proteins used for the analysis.
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